Contribution of 1173C > T polymorphism in the VKORC1 gene to warfarin dose requirements in Han Chinese patients receiving anticoagulation

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 1, 2011, Pages 23-29

  Yang, J ^a   Huang, C ^b   Shen, Z ^b   Miao, L ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

CYP2C9; Gene polymorphism; VKORC1 (1173C > T); Warfarin therapy

Indexed keywords

OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN;

ADOLESCENT; ADULT; AGE; AGED; ALLELE; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD SAMPLING; BODY WEIGHT; CHINESE; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PROTHROMBIN TIME; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; WILD TYPE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CHINA; FEMALE; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; WARFARIN;

EID: 78650840777     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP49023     Document Type: Article

References (26)

1. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001; 40: 587-603. (Pubitemid 32758581)
2. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999; 353: 717-719.
3. Higashi MK, Veenstra DL, Kondo LM,Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002; 287: 1690-1698.
4. Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics. 1997; 7: 405-409.
5. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K,Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Muller CR, Strom TM, Oldenburg J. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiencytype2. Nature. 2004; 427: 537-541.
6. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature. 2004; 427: 541-544.
7. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, Loriot MA. Cytochrome P450 2C9 (CYP2C9) and vitaminK epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005; 106: 135-140. (Pubitemid 40967184)
8. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N,Wallerman O, Melhus H, Wadelius C, Bentley D, Deloukas P.Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005; 5: 262-270.
9. Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic diffdrences in warfarin sensitivity. Hum Mol Genet. 2005; 14: 1745-1751.
10. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V.A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005; 105: 645-649.
11. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod H. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005; 352: 2285-2293. (Pubitemid 40740552)
12. Miao L, Yang J, Huang C, Shen Z. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol. 2007; 63: 1135-1141.
13. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ; PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003; 348: 1425-1434.
14. Sun YH, Hu DY. The efficiency and safety of anticoagulation therapy in atrial fibrillation in Chinese. Clin J Intern Med. 2004; 43: 258-260.
15. Yamaguchi T. Optimal intensity of warfain therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective randomized trial. Stroke. 2000; 31: 817-821. (Pubitemid 30198421)
16. Huang C, Yang J, Du Y, Miao L. Measurement of Free Concentrations of Highly Protein-Bound Warfarin in Plasma by Ultra Performance Liquid Chromatography - Tandem Mass Spectrometry and its Correlation with the International Normalized Ratio. CLINICA CHIMICA ACTA. 2008; 393: 85-89.
17. Excoffier Laval L G, Schneider S.arlequin Version 3.0: an integrated software package for population genetics data analysis. Evolutionary Bioinformatics Online. 2005; 1: 47-50.
18. Schalekamp T, Brassé BP, Roijers JF, Chahid Y, van Geest-Daalderop JH, de Vries-Goldschmeding H, van Wijk EM, Egberts AC, de Boer A. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther. 2006; 80: 13-22.
19. Li T, Lange LA, Li X, Susswein L, Bryant B, Malone R, Lange EM, Huang TY, Stafford DW, Evans JP. Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. J Med Genet. 2006; 43: 740-744.
20. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005; 10: 2329-2333. (Pubitemid 41510803)
21. Haug kBF, Sharikabad MN, Kringen MK, Narum S, Sjaatil ST, Johansen PW, Kierulf P, Seljeflot I, Arnesen H, Brørs O. Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction. Thrombosis Journal. 2008; 6: 7.
22. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 2007; 7: 99-111.
23. Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I. Different contributions of polymorphisms inVKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.Pharmacogenet Genomics. 2006; 16: 101-110.
24. Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS,Mohuczy D, Gaston KL,Waddell CD, Chirico MJ, Johnson JA. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther. 2006; 79: 291-302.
25. Lee SC, Ng SS, Oldenburg J, Chong PY, Rost S, Guo JY, Yap HL, Rankin SC, Khor HB, Yeo TC. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther. 2006; 79: 197-205.
26. Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, Muller CR, Wienker TF, Oldenburg J. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost. 2005; 94: 773-779. (Pubitemid 41489236)